Routine nebulized ipratropium and albuterol together are better than either alone in COPD

D. Auerbach, C. Hill, R. Baughman, Michael Boyars, S. Braun, A. S. Buist, S. C. Campbell, T. Chick, B. Cohen, G. Colice, L. Dunn, M. Friedman, M. Gilman, A. Gorin, N. Gross, S. Jenkinson, B. Levine, R. Libert, J. Liu, G. MestasR. O'Connor, J. Ramsdell, J. Rowlands, C. W. Serby, A. Warmer, S. Weiss

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Study objective: We compared the long-term safety and efficacy of the combination ipratropium bromide (IB) and albuterol sulfate (ALB) inhalation solution with that of each separate component using three-times-daily administration. Design: Using a parallel design, we randomized patients to receive 3.0 mg ALB, 0.5 mg IB, or the combination by small-volume nebulizer (SVN) for 85 days. Subjects were allowed to use up to two extra doses of study medication daily for control of symptoms on an as-needed basis. The main efficacy evaluation was the acute pulmonary function response to an aerosol of the maintenance study medication over the course of the investigation. Physician global evaluation, subject quality of life assessments, COPD symptom scores, and twice-daily peak expiratory flow rate (PEFR) were also assessed over the study period. Setting: Twenty-five centers participated in the investigation. Patients: We studied 652 patients with moderate to severe COPD. Measurements and results: Over the course of the study, the acute spirometric response and evening PEFR values with the SVN combination of IB plus ALB were statistically significantly better compared to ALB or IB alone. The quality of life scores, physician global evaluations, symptom scores, and morning PEFR scores were unchanged over the duration of the study in all treatment groups. There was no significant difference in adverse events in the three treatment groups. Conclusions: In patients with COPD, maintenance SVN therapy with IB and ALB provides better bronchodilation than either therapy alone without increasing side effects.

Original languageEnglish (US)
Pages (from-to)1514-1521
Number of pages8
JournalChest
Volume112
Issue number6
StatePublished - 1997
Externally publishedYes

Fingerprint

Ipratropium
Albuterol
Chronic Obstructive Pulmonary Disease
Peak Expiratory Flow Rate
Nebulizers and Vaporizers
Symptom Assessment
Maintenance
Quality of Life
Physicians
Therapeutics
Aerosols
Inhalation
Ipratropium Drug Combination Albuterol
Safety
Lung

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Auerbach, D., Hill, C., Baughman, R., Boyars, M., Braun, S., Buist, A. S., ... Weiss, S. (1997). Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest, 112(6), 1514-1521.

Routine nebulized ipratropium and albuterol together are better than either alone in COPD. / Auerbach, D.; Hill, C.; Baughman, R.; Boyars, Michael; Braun, S.; Buist, A. S.; Campbell, S. C.; Chick, T.; Cohen, B.; Colice, G.; Dunn, L.; Friedman, M.; Gilman, M.; Gorin, A.; Gross, N.; Jenkinson, S.; Levine, B.; Libert, R.; Liu, J.; Mestas, G.; O'Connor, R.; Ramsdell, J.; Rowlands, J.; Serby, C. W.; Warmer, A.; Weiss, S.

In: Chest, Vol. 112, No. 6, 1997, p. 1514-1521.

Research output: Contribution to journalArticle

Auerbach, D, Hill, C, Baughman, R, Boyars, M, Braun, S, Buist, AS, Campbell, SC, Chick, T, Cohen, B, Colice, G, Dunn, L, Friedman, M, Gilman, M, Gorin, A, Gross, N, Jenkinson, S, Levine, B, Libert, R, Liu, J, Mestas, G, O'Connor, R, Ramsdell, J, Rowlands, J, Serby, CW, Warmer, A & Weiss, S 1997, 'Routine nebulized ipratropium and albuterol together are better than either alone in COPD', Chest, vol. 112, no. 6, pp. 1514-1521.
Auerbach D, Hill C, Baughman R, Boyars M, Braun S, Buist AS et al. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997;112(6):1514-1521.
Auerbach, D. ; Hill, C. ; Baughman, R. ; Boyars, Michael ; Braun, S. ; Buist, A. S. ; Campbell, S. C. ; Chick, T. ; Cohen, B. ; Colice, G. ; Dunn, L. ; Friedman, M. ; Gilman, M. ; Gorin, A. ; Gross, N. ; Jenkinson, S. ; Levine, B. ; Libert, R. ; Liu, J. ; Mestas, G. ; O'Connor, R. ; Ramsdell, J. ; Rowlands, J. ; Serby, C. W. ; Warmer, A. ; Weiss, S. / Routine nebulized ipratropium and albuterol together are better than either alone in COPD. In: Chest. 1997 ; Vol. 112, No. 6. pp. 1514-1521.
@article{299f39b2bc704de5b57b7b575a4c9e73,
title = "Routine nebulized ipratropium and albuterol together are better than either alone in COPD",
abstract = "Study objective: We compared the long-term safety and efficacy of the combination ipratropium bromide (IB) and albuterol sulfate (ALB) inhalation solution with that of each separate component using three-times-daily administration. Design: Using a parallel design, we randomized patients to receive 3.0 mg ALB, 0.5 mg IB, or the combination by small-volume nebulizer (SVN) for 85 days. Subjects were allowed to use up to two extra doses of study medication daily for control of symptoms on an as-needed basis. The main efficacy evaluation was the acute pulmonary function response to an aerosol of the maintenance study medication over the course of the investigation. Physician global evaluation, subject quality of life assessments, COPD symptom scores, and twice-daily peak expiratory flow rate (PEFR) were also assessed over the study period. Setting: Twenty-five centers participated in the investigation. Patients: We studied 652 patients with moderate to severe COPD. Measurements and results: Over the course of the study, the acute spirometric response and evening PEFR values with the SVN combination of IB plus ALB were statistically significantly better compared to ALB or IB alone. The quality of life scores, physician global evaluations, symptom scores, and morning PEFR scores were unchanged over the duration of the study in all treatment groups. There was no significant difference in adverse events in the three treatment groups. Conclusions: In patients with COPD, maintenance SVN therapy with IB and ALB provides better bronchodilation than either therapy alone without increasing side effects.",
author = "D. Auerbach and C. Hill and R. Baughman and Michael Boyars and S. Braun and Buist, {A. S.} and Campbell, {S. C.} and T. Chick and B. Cohen and G. Colice and L. Dunn and M. Friedman and M. Gilman and A. Gorin and N. Gross and S. Jenkinson and B. Levine and R. Libert and J. Liu and G. Mestas and R. O'Connor and J. Ramsdell and J. Rowlands and Serby, {C. W.} and A. Warmer and S. Weiss",
year = "1997",
language = "English (US)",
volume = "112",
pages = "1514--1521",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Routine nebulized ipratropium and albuterol together are better than either alone in COPD

AU - Auerbach, D.

AU - Hill, C.

AU - Baughman, R.

AU - Boyars, Michael

AU - Braun, S.

AU - Buist, A. S.

AU - Campbell, S. C.

AU - Chick, T.

AU - Cohen, B.

AU - Colice, G.

AU - Dunn, L.

AU - Friedman, M.

AU - Gilman, M.

AU - Gorin, A.

AU - Gross, N.

AU - Jenkinson, S.

AU - Levine, B.

AU - Libert, R.

AU - Liu, J.

AU - Mestas, G.

AU - O'Connor, R.

AU - Ramsdell, J.

AU - Rowlands, J.

AU - Serby, C. W.

AU - Warmer, A.

AU - Weiss, S.

PY - 1997

Y1 - 1997

N2 - Study objective: We compared the long-term safety and efficacy of the combination ipratropium bromide (IB) and albuterol sulfate (ALB) inhalation solution with that of each separate component using three-times-daily administration. Design: Using a parallel design, we randomized patients to receive 3.0 mg ALB, 0.5 mg IB, or the combination by small-volume nebulizer (SVN) for 85 days. Subjects were allowed to use up to two extra doses of study medication daily for control of symptoms on an as-needed basis. The main efficacy evaluation was the acute pulmonary function response to an aerosol of the maintenance study medication over the course of the investigation. Physician global evaluation, subject quality of life assessments, COPD symptom scores, and twice-daily peak expiratory flow rate (PEFR) were also assessed over the study period. Setting: Twenty-five centers participated in the investigation. Patients: We studied 652 patients with moderate to severe COPD. Measurements and results: Over the course of the study, the acute spirometric response and evening PEFR values with the SVN combination of IB plus ALB were statistically significantly better compared to ALB or IB alone. The quality of life scores, physician global evaluations, symptom scores, and morning PEFR scores were unchanged over the duration of the study in all treatment groups. There was no significant difference in adverse events in the three treatment groups. Conclusions: In patients with COPD, maintenance SVN therapy with IB and ALB provides better bronchodilation than either therapy alone without increasing side effects.

AB - Study objective: We compared the long-term safety and efficacy of the combination ipratropium bromide (IB) and albuterol sulfate (ALB) inhalation solution with that of each separate component using three-times-daily administration. Design: Using a parallel design, we randomized patients to receive 3.0 mg ALB, 0.5 mg IB, or the combination by small-volume nebulizer (SVN) for 85 days. Subjects were allowed to use up to two extra doses of study medication daily for control of symptoms on an as-needed basis. The main efficacy evaluation was the acute pulmonary function response to an aerosol of the maintenance study medication over the course of the investigation. Physician global evaluation, subject quality of life assessments, COPD symptom scores, and twice-daily peak expiratory flow rate (PEFR) were also assessed over the study period. Setting: Twenty-five centers participated in the investigation. Patients: We studied 652 patients with moderate to severe COPD. Measurements and results: Over the course of the study, the acute spirometric response and evening PEFR values with the SVN combination of IB plus ALB were statistically significantly better compared to ALB or IB alone. The quality of life scores, physician global evaluations, symptom scores, and morning PEFR scores were unchanged over the duration of the study in all treatment groups. There was no significant difference in adverse events in the three treatment groups. Conclusions: In patients with COPD, maintenance SVN therapy with IB and ALB provides better bronchodilation than either therapy alone without increasing side effects.

UR - http://www.scopus.com/inward/record.url?scp=3042804527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042804527&partnerID=8YFLogxK

M3 - Article

C2 - 9404747

AN - SCOPUS:3042804527

VL - 112

SP - 1514

EP - 1521

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -